[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hepatocellular-carcinoma-recurrent\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hepatocellular-carcinoma-recurrent":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,74,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100602030","therabionic-p1-device-in-subjects-with-advanced-hepatocellular-carcinoma-100602030",false,"NCT07118202","TheraBionic P1 Device in Subjects With Advanced Hepatocellular Carcinoma","TheraBionic P1 Device for Patients With Advanced Hepatocellular Carcinoma (HCC) Who Fail First and Second Line Therapy","TARGET-HCC","Inclusion Criteria:\n\n* Patients with advanced hepatocellular carcinoma (HCC) (defined as a liver tumor not eligible for local therapies given the extent of disease or a livor tumor that recurred after local therapy)\n* Patients who have failed at least two lines of therapy\\* or who are no longer eligible for any line of standard therapy or who are intolerant to at least two lines of therapy.\n* Patients with evaluable disease\n* Patients must be ≥ 22 years old and must be able to understand and sign an informed consent.\n* Female patients of childbearing potential and their partners and male patients must agree to use adequate contraception during the period of study treatment.\n* Patients with a life expectancy of at least 3 months\n\nExclusion Criteria:\n\n* Patients with known active secondary malignancy, unless, in the opinion of the investigator, it is unlikely to interfere with the safety and efficacy of the endpoints\n* Patients taking any other investigational drugs\n* Patients with active oral mucosal inflammation, ulceration, or other pathology that could interfere with the use of the device\n* Patients receiving calcium channel blockers and any agent blocking L-type of T-type Voltage Gated Calcium Channels, e.g., amlodipine, nifedipine, ethosuximide, ascorbic acid (vitamin C), etc. unless their medical treatment is discontinued to prior to treatment on study. Patients must agree to abstain from using calcium channel blockers and any agent blocking L-type or T-type voltage gated calcium channels for the duration of treatment on study.\n* Patients who are breastfeeding. If a breastfeeding participant would like to be part of this study, breastfeeding must be discontinued.\n* Patients that do not agree to be followed according to the study protocol or have cognitive or physical inability to use the device for the prescribed period and frequency (three 60-minute treatments in the morning, middle of the day, and evening)\n* Patients with a known severe (e.g., anaphylactic) allergy to nickel","ALL","22 Years",{"count":20,"type":21},198,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if the TheraBionic P1 device given to patients with advanced hepatocellular carcinoma (HCC) who have no standard of care options can affect patients survival. The main questions it aims to answer are:\n\n* will the TheraBionic P1 device affect overall survival in advance HCC\n* the long term safety and tolerability of the TheraBionic P1 device\n* assessment of how the disease responded to the TheraBionic P1 device",[27],"Hepatocellular Carcinoma Recurrent","RECRUITING","2026-04-07",{"date":31,"type":32},"2026-04-13","ACTUAL",{"date":34,"type":32},"2025-10-20",{"date":36,"type":21},"2028-08-31",{"name":38,"class":39},"Barbara Ann Karmanos Cancer Institute","OTHER",6,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100630599","gnb4-and-riplet-gene-methylation-combined-detection-kit-for-hepatocellular-carcinoma-recurrence-monitoring-100630599","NCT07489768","GNB4 and Riplet Gene Methylation Combined Detection Kit for Hepatocellular Carcinoma Recurrence Monitoring","A Prospective, Multicenter Observational Clinical Study of the GNB4 and Riplet Gene Methylation Combined Detection Kit (Real-time PCR) for Post-treatment Recurrence Monitoring in Hepatocellular Carcinoma","CCGLC-019","Inclusion Criteria:\n\nParticipants must meet criterion (1) and any one of criteria (2) through (4):\n\n1. Adults aged 18 years or older;\n2. Patients with confirmed hepatocellular carcinoma or highly suspected hepatocellular carcinoma who are planned to undergo one or more of the following treatments: liver resection, liver transplantation, ablation, or transarterial chemoembolization (TACE);\n3. Patients who have previously received antitumor therapy but remain in a tumor-bearing state of hepatocellular carcinoma and are planned to undergo one or more of the following treatments: liver resection, liver transplantation, ablation, or transarterial chemoembolization (TACE);\n4. Post-treatment patients with primary hepatocellular carcinoma who have already undergone one or more of the following treatments: liver resection, liver transplantation, ablation, or transarterial chemoembolization (TACE), and whose result of the study assay before treatment was positive.\n\nExclusion Criteria:\n\n1. Patients with hepatocellular carcinoma who will not undergo any of the following treatments: liver resection, liver transplantation, ablation, or transarterial chemoembolization (TACE);\n2. Patients enrolled as highly suspected hepatocellular carcinoma whose final diagnosis according to the clinical reference standard is not primary hepatocellular carcinoma, or for whom it cannot be determined whether the disease is primary hepatocellular carcinoma;\n3. Patients whose samples collected before hepatocellular carcinoma treatment were not stored in accordance with protocol requirements;\n4. Patients whose samples collected before hepatocellular carcinoma treatment are insufficient in volume to meet the testing requirements.\n\nAny enrolled participant who is subsequently excluded from the clinical study will be documented, and the reason for exclusion will be clearly recorded.","18 Years",{"count":51,"type":21},162,"OBSERVATIONAL","This is a prospective, multicenter, observational longitudinal study designed to evaluate the clinical performance of the GNB4 and Riplet Gene Methylation Combined Detection Kit (Real-time PCR) for monitoring recurrence after treatment of hepatocellular carcinoma.\n\nAdult patients with confirmed or highly suspected hepatocellular carcinoma who are planned to undergo, or have undergone, liver resection, liver transplantation, ablation, or transarterial chemoembolization (TACE) will be enrolled. Plasma samples will be collected before treatment and during follow-up after treatment. The test results of the study kit will be compared with the clinical reference standard, which is based on comprehensive clinical diagnosis according to routine practice and relevant guidelines.\n\nThe study aims to assess whether this methylation-based blood test can help identify recurrence of hepatocellular carcinoma after treatment. The main clinical performance measures include sensitivity in patients with recurrent disease, specificity in patients without recurrence, and overall agreement with the clinical reference standard.",[55,27],"Hepatocellular Carcinoma (HCC)",[57,58,59,60,61,62,63],"Hepatocellular Carcinoma","Recurrence Monitoring","DNA Methylation","Circulating Cell-Free DNA","GNB4","Riplet","Real-time PCR","NOT_YET_RECRUITING","2026-03-18",{"date":67,"type":32},"2026-03-24",{"date":69,"type":21},"2026-04-01",{"date":71,"type":21},"2029-06-01",{"name":73,"class":39},"Tongji Hospital",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100535624","phase-2-safety-of-atezolizumab-bevacizumab-in-liver-transplanted-patients-with-advanced-hepatocellular-carcinoma-100535624","NCT06254248","Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma","IMMUNO-TH","Inclusion Criteria:\n\n* All patients over 18 and under 90 years old:\n* who underwent LT more than 6 months ago (to prevent the higher risk of ACR which exists within the first months after LT and to deal with populations with a lowered immunosuppressive regimen long after LT)\n* with HCC recurrence diagnosis according to the EASL diagnostic criteria (33)\n* with advanced HCC not accessible to surgery and locoregional treatment\n* with at least one measurable untreated lesion\n* With a proposal for Atezo-Beva in first line treatment made in a multidisciplinary meeting\n* Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained within 14 days prior to initiation of study treatment, unless otherwise specified:\n\n  * ANC ≥ 1.5 x 109\u002FL (1500\u002FµL) without granulocyte colony-stimulating factor support\n  * Lymphocyte count ≥ 0.5 x 109\u002FL (500\u002FµL)\n  * Platelet count ≥ 75 x 109\u002FL (75,000\u002FµL) without transfusion\n  * Hemoglobin ≥ 90 g\u002FL (9 g\u002FdL). Patients may be transfused to meet this criterion.\n  * AST, ALT ≤ 5 x upper limit of normal (ULN)\n  * Serum bilirubin ≤ 3x ULN\n  * creatinine clearance≥40 mL\u002Fmin (calculated using the Cockcroft-Gault formula)\n  * For patients not receiving therapeutic anticoagulation: INR or aPTT ≤ 2x ULN\n  * Urine dipstick for proteinuria \\\u003C 2+ (within 7 days prior to initiation of study treatment). Patients discovered to have ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate \\\u003C1 g of protein in 24 hours\n* ECOG Performance Status of 0 or 1\n* For women of childbearing potential and men: agreement to remain abstinent or use effective contraception during treatment and at least :\n\n  * 5 months after the end of the treatment with atezolizumab,\n  * 6 months after the end of the treatment with bevacizumab\n* Child-Pugh class A\n\nExclusion Criteria:\n\n* History of ACR within 3 months before starting Atezo-Beva treatment\n* Banff score for ACR ≥ 3 on liver biopsy performed before the initiation of the treatment\n* Pregnant or breastfeeding woman\n* Patient not affiliated to a beneficiary or entitled social security scheme or to the PUMA\n* Patient not having signed consent\n* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT-scan\n* History of malignancy other than HCC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death\n* Untreated or incompletely treated esophageal and\u002For gastric varices with bleeding or high-risk for bleeding\n* A prior bleeding event due to esophageal and\u002For gastric varices within 6 months prior to initiation of study treatment.\n* Inadequately controlled arterial hypertension (defined as systolic blood pressure (BP) ≥ 160 mmHg and\u002For diastolic blood pressure \\> 100 mmHg), based on an average of ≥ 3 BP readings on ≥ 2 sessions Anti-hypertensive therapy to achieve these parameters is allowable.\n* Prior history of hypertensive crisis or hypertensive encephalopathy\n* History of intestinal obstruction and\u002For clinical signs or symptoms of GI obstruction including sub-occlusive disease related to the underlying disease or requirement for routine parenteral hydration\n* Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture\n* Metastatic disease that involves major airways or blood vessels, or centrally located mediastinal tumor masses\n* Hypersensitivity to the active substance or to any of the excipients of the SmPC of bevacizumab and the SmPC of atezolizumab\n* Hypersensitivity to Chinese Hamster Ovary (CHO) cell products or other recombinant human or humanised antibodies\n* Prior arterial thromboembolic reactions including cerebrovascular accidents, transient ischaemic attacks and myocardial infarctions;\n* Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina\n* In case of proteinuria \\> 1g in 24 hours\n* History of leptomeningeal disease\n* Active tuberculosis\n* Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia","90 Years",{"count":83,"type":21},50,[85],"PHASE2","The prognosis of liver transplanted (LT) patients with recurrence of hepatocellular carcinoma (HCC), especially those with progression after locoregional treatment or advanced HCC, remains poor. Current treatment modalities involve tyrosine kinase inhibitors (TKIs) characterized by a low response rate and often poor tolerability. Encouraging findings from the Imbrave 150 study, demonstrating increased survival rates coupled with favorable treatment tolerance, prompt the investigators to consider the potential of offering the combination of treatment with Atezolizumab-Bevacizumab (Atezo-Beva) to patients with LT. No data regarding the safety and efficacy of this new combination are available for patients with LT as they were not included in Imbrave 150. Immunosuppression after LT is low when compared to essentially all other organ recipients, liver recipients are considered with lower immunological risk. However, the use of ICIs has been associated with a risk of hepatic rejection in LT patients. In this study, in order to prevent acute cellular rejection (ACR) occurrence, we propose to adopt a standardized immunosuppressive regimen closed to the one used immediately after LT but with lower therapeutic goals for tacrolimus and everolimus to allow immunotherapy treatment to be effective. The better tolerance of liver grafts will probably lead to less risk of rejection with Atezo-Beva than in other organ transplants.",[88,27,89],"Liver Transplant","Systemic Treatment",[91,92,93,94,95],"HCC","systemic therapy","graft rejection","immunotherapy","Atezolizumab-Bevacizumab","2026-03-06",{"date":98,"type":32},"2026-03-10",{"date":100,"type":32},"2026-01-22",{"date":102,"type":21},"2030-01-01",{"name":104,"class":39},"Assistance Publique - Hôpitaux de Paris",10,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":40},"100471365","phase-1-a-study-of-scg101-in-the-treatment-of-subjects-with-hepatitis-b-virus-related-hepatocellular-carcinoma-100471365","NCT05417932","A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma","A Phase 1\u002F 2a, Multicenter Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma","TCR-T","Main Inclusion Criteria:\n\n* Histologically or cytologically confirmed Hepatocellular carcinoma (HCC)\n* Subjects with HCC who have received at least 2 standard systemic therapies\n* HLA-A \\*02\n* BCLC stage B or C\n* Child-pugh score ≤ 7\n* Serum HBeAg negative, serum (or tumor tissue) HBsAg positive, and serum HBV-DNA must be 2 × 1000 IU\u002Fml\n* Have at least one measurable leasion at baseline as per mRECIST and RECIST v1.1 criteria\n* Life expectancy of 3 months or greater\n* Ability to provide informed consent form\n* Ability to comply with all the study procedures\n\nMain Exclusion Criteria:\n\n* Subjects with history of another primary cancer\n* Untreated or active central nervous system (CNS) or leptomeningeal metastasis, or history of hepatic encephalopathy, or other clinically significant CNS diseases\n* Autoimmune diseases requiring immunosuppressive therapy (except topical medication) or subjects with significant persistent immune rejection\n* Known history of neurological or mental disorder, including epilepsy or dementia\n* Known history of positive results for human immunodeficiency virus (HIV) 1 or 2 or known acquired immunodeficiency syndrome (AIDS)\n* Prior exposure to any cell therapy such as, but not limited to killer (NK) cells, cytokine-induced killer (CIK) cells, dendritic cells (DC), cytotoxic T lymphocytes (CTL), stem cell therapy, CAR T\u002FTCR T cell therapy\n* Allergy to immunotherapy drugs and lymphodepleting chemotherapy (cyclophosphamide and fludarabine)\n* Any subjects who cannot be evaluated by either triphasic liver CT or triphasic MRI because of allergy or other contraindication to both CT and MRI contrast agents\n* Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation","70 Years",{"count":116,"type":21},46,[118,85],"PHASE1","This Phase 1\u002F 2a study is a multicenter study to evaluate the safety, tolerability and efficacy of SCG101 in subjects with hepatitis B virus-related hepatocellular carcinoma",[121,27],"Hepatitis B Virus Related Hepatocellular Carcinoma",[91,123,124],"Hepatitis B Virus Related","HCC Recurrent","2025-02-16",{"date":127,"type":32},"2025-02-18",{"date":129,"type":32},"2022-10-26",{"date":131,"type":21},"2025-10",{"name":133,"class":134},"SCG Cell Therapy Pte. Ltd.","INDUSTRY"]